Altre lingue Bristol-Myers Squibb Company Borsa Italiana

Azioni

4BMY

US1101221083

Tempo reale stimato Tradegate Altri mercati azionari 21:50:07 26/06/2024			Variaz. 5gg	Var. 1 gen.
39,88 ^EUR	+5,04%		-0,09%	-18,19%

18:28	Le storie più importanti di mezzogiorno: Southwest taglia le previsioni per il secondo trimestre; HHS ridurrà i costi per gli iscritti a Medicare su 64 farmaci; Bosch sta valutando un'offerta di acquisizione per Whirlpool; Novo Nordisk registrerà una svalutazione di 816,2 milioni di dollari.	MT
17:27	L'Amministrazione Biden ridurrà i costi di 64 farmaci da prescrizione per gli iscritti a Medicare	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	18:28
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	17:27
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	17:08
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	16:35
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	24/06
Bristol Myers : approbation accélérée en cancer colorectal	24/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	22/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	21/06
US FDA approves Bristol Myers' colorectal cancer therapy	21/06
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06
Bristol Myers : demande validée pour Opdivo sous-cutané	21/06
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	21/06
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	20/06
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	19/06
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	18/06
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	18/06
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	18/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

Il CEO di Bristol-Myers dice che l'azienda è in fase di transizione

09 gennaio 2024 alle 19:06